Fresenius Medical Care AG
XMUN:FME
Intrinsic Value
Fresenius Medical Care AG & Co. KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. [ Read More ]
The intrinsic value of one
FME
stock under the Base Case scenario is
50.23
EUR.
Compared to the current market price of 37.77 EUR,
Fresenius Medical Care AG
is
Undervalued by 25%.
Fresenius Medical Care AG's market capitalization is 22.2B EUR.
FME stock price is 37.77 EUR.
FME stock price (37.77 EUR) is 25% less than its Intrinsic Value (50.23 EUR).
FME stock price (37.77 EUR) is 44% less than its Relative Value (67.66 EUR). Open Relative Valuation
FME.
FME's Revenue has grown by 0% over the past 12 months.
FME has positive Operating Income for the last twelve months.
FME's ROIC (Return on Invested Capital) has decreased in the last 3 years from 5% to 3%.
FME's Revenue is forecast to grow at a rate of 4% per year over the next 3 years.
FME's Revenue has been growing by 3% per year for the last 3 years.
FME's ROE (Return on Equity) has decreased in the last 3 years from 9% to 4%.
FME's ROE (Return on Equity) for the past 12 months is very low and is equal to 4%.
FME's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 3%.
FME has positive Net Income for the last twelve months.
FME has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
FME's short-term assets (9B EUR) exceed its short-term liabilties (6B EUR).
FME's D/E (Debt to Equity) is very low and is equal to 0.8.
FME has a very low three-year average ROIC (Return on Invested Capital): 4%. The company is not efficient at using invested capital to generate operating income.
FME has positive Gross Profit for the last twelve months.
FME's long-term assets (34B EUR) exceed its long-term liabilties (20B EUR).
FME has positive Free Cash Flow for the last twelve months.
FME's Altman Z-Score is equal to 1.85.
FME has positive Net Debt. This means that the company has more debt (11B EUR) than cash and short-term investments (2B EUR).
FME generates enough operating income (1B EUR) to cover interest payments on its debt (395m EUR).
Valuation Backtest
Fresenius Medical Care AG
Run backtest to discover the historical profit from buying and selling
FME
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Fresenius Medical Care AG
Balance Sheet Decomposition
Fresenius Medical Care AG
| Current Assets | 8.7B |
| Cash & Short-Term Investments | 1.6B |
| Receivables | 3.6B |
| Other Current Assets | 3.4B |
| Non-Current Assets | 25.2B |
| Long-Term Investments | 1.3B |
| PP&E | 7.5B |
| Intangibles | 16B |
| Other Non-Current Assets | 507.5m |
| Current Liabilities | 6.1B |
| Accounts Payable | 762.1m |
| Short-Term Debt | 456.9m |
| Other Current Liabilities | 4.9B |
| Non-Current Liabilities | 14.2B |
| Long-Term Debt | 10.5B |
| Other Non-Current Liabilities | 3.7B |
Earnings Waterfall
Fresenius Medical Care AG
|
Revenue
|
19.5B
EUR
|
|
Cost of Revenue
|
-14.5B
EUR
|
|
Gross Profit
|
4.9B
EUR
|
|
Operating Expenses
|
-3.6B
EUR
|
|
Operating Income
|
1.3B
EUR
|
|
Other Expenses
|
-779.3m
EUR
|
|
Net Income
|
499m
EUR
|
Free Cash Flow Analysis
Fresenius Medical Care AG
FME Profitability Score
Profitability Due Diligence
Fresenius Medical Care AG's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Fresenius Medical Care AG's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
FME Solvency Score
Solvency Due Diligence
Fresenius Medical Care AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Fresenius Medical Care AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FME Price Targets Summary
Fresenius Medical Care AG
Shareholder Return
FME Price
Fresenius Medical Care AG
| Average Annual Return | -15.04% |
| Standard Deviation of Annual Returns | 22.79% |
| Max Drawdown | -64% |
| Market Capitalization | 22.2B EUR |
| Shares Outstanding | 586 826 900 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Fresenius Medical Care AG
Country
Industry
Market Cap
Dividend Yield
Description
Fresenius Medical Care AG & Co. KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 123,106 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The firm also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The firm supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Contact
IPO
Employees
Officers
The intrinsic value of one
FME
stock under the Base Case scenario is
50.23
EUR.
Compared to the current market price of 37.77 EUR,
Fresenius Medical Care AG
is
Undervalued by 25%.
You don't have any saved screeners yet
